News
AOP Health Launches Packaging Facility in Vienna
10. 8. 2022AOP Health starts Research for Leukemia Treatment
28. 7. 2022AOP Health presents final results from its CONTINUATION-PV study -up to 7.5 years treatment with BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera patients - at EHA 2022 Annual Meeting
13. 6. 2022
AOP Health headquarters team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Health headquarters using the link below.
In the field of rare diseases the AOP Health team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.